Immunogenicity of a hexavalent vaccine co-administered with 7-valent pneumococcal conjugate vaccine: Findings from the national immunization program in the Netherlands

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 6, 2012, Pages 743-748

  Whelan, Jane ^a,b   Hahne, Susan ^a   Berbers, Guy ^a   Van Der Klis, Fiona ^a   Wijnands, Yvonne ^a   Boot, Hein ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

Diphtheria tetanus acellular pertussis vaccines; Haemophilus vaccines; Hepatitis B vaccines; Immunogenicity; Infants; Pneumococcal vaccines

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FILAMENTOUS HEMAGGLUTININ; HEMAGGLUTININ; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PERTUSSIS ANTIBODY; PNEUMOCOCCAL SUFACE ANTIBODY; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADOLESCENT; ANTIGEN DETECTION; ARTICLE; CHILD; CONTROLLED STUDY; DIPHTHERIA; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; INFANT; INFECTION RISK; MALE; PERTUSSIS; POLIOMYELITIS; SCHOOL CHILD; SEROCONVERSION; SEROPROTECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

BACTERIAL CAPSULES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; NETHERLANDS; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED;

EID: 84863642805     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19642     Document Type: Article

References (42)

1. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care 2003; 9:6-12; PMID:12564784.
2. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006; 25:507-12; PMID:16732148; http://dx.doi.org/10.1097/ 01.inf.0000222413.47344.23.
3. Boot HJ, Schipper CM. Simultaneous vaccination with Prevenar and multicomponent vaccines for children: interference or no interference? Hum Vaccin 2009; 5:15-7; PMID:18690011; http://dx.doi.org/10.4161/hv.5.1.6520.
4. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361:1521-3; PMID:12737866; http://dx.doi.org/10.1016/ S0140-6736(03)13171-6.
5. GlaxoSmithKline Biologicals S.A. Annex 1. Summary of Product characteristics: Infanrix Hexa, Last updated: 14/09/2011.
6. European Medicines Agency. Scientific conclusions and grounds for the suspension of the marketing authorisation of hexavac presented by the EMEA 2005.
7. Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009; 8:663-78; PMID:19485747; http://dx.doi.org/10.1586/erv.09.32.
8. Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J 2005; 24:70-7; PMID:15665713; http://dx.doi.org/10.1097/01.inf.0000148923.46453.48.
9. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/ Hib combination vaccine in healthy infants. Vaccine 2006; 24:4727-36; PMID:16616973; http://dx.doi.org/10. 1016/j.vaccine.2006.03.032.
10. Kitchin NR, Southern J, Morris R, Hemme F, Thomas S, Watson MW, et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 2007; 92:11-6; PMID:16670121; http://dx.doi.org/10.1136/adc.2005.076109.
11. Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006; 25:312-9; PMID:16567982; http://dx.doi.org/10.1097/01.inf.0000207483. 60267.e7.
12. Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet JM, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/ Hib in the first and 2nd year of life. BMC Infect Dis 2010; 10:9; PMID:20078876; http://dx.doi.org/10.1186/1471- 2334-10-9.
13. Zanetti AR, Romanò L, Giambi C, Pavan A, Carnelli V, Baitelli G, et al.; study group. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010; 10:755-61; PMID:20884297; http://dx.doi.org/10.1016/S1473-3099(10)70195-X.
14. Zinke M, Disselhoff J, Gartner B, Jacquet JM. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccin 2010; 6; PMID:20009522; http://dx.doi.org/10.4161/ hv.6.2.10117.
15. Kalies H, Grote V, Siedler A, Gröndahl B, Schmitt HJ, von Kries R. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure. Vaccine 2008; 26:2545-52; PMID:18403069; http://dx.doi.org/10.1016/j.vaccine.2008.03.001.
16. Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, Hak E, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010; 16:816-23; PMID:20409372.
17. World Health Organisation. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 2009; 40:405-20.
18. Tichmann I, Grunert D, Habash S, Preidel H, Schult R, Pfletschinger U, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin 2006; 2:249-54; PMID:17106268; http://dx.doi.org/10. 4161/hv.2.6.3432.
19. Hsu LC, Lin SR, Hsu HM, Chao WH, Hsieh JT, Wang MC, et al. Ethnic differences in immune responses to hepatitis B vaccine. Am J Epidemiol 1996; 143:718-24; PMID:8651234.
20. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010; 10:338-49; PMID:20417416; http://dx.doi.org/10.1016/S1473-3099(10)70049-9.
21. Domínguez A, Plans P, Costa J, Torner N, Cardenosa N, Batalla J, et al. Seroprevalence of measles, rubella and mumps antibodies in Catalonia, Spain: results of a cross-sectional study. Eur J Clin Microbiol Infect Dis 2006; 25:310-7; PMID:16786377; http://dx.doi.org/10.1007/s10096-006-0133-z.
22. Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 2008; 121:1091-9; PMID:18450852; http://dx.doi.org/10.1542/peds.2007-1575.
23. Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25:6958-64; PMID:17714836; http://dx.doi.org/10.1016/j.vaccine.2007.06.059.
24. Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams IT, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008; 27:881-5; PMID:18756185; http://dx.doi.org/10.1097/INF.0b013e31817702ba.
25. Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M, Coppola RC, et al.; Study Group. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-84; PMID:16226616; http://dx.doi.org/10.1016/S0140-6736(05)67568-X.
26. Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect 2008; 57:404-9; PMID:18829116; http://dx.doi.org/10.1016/j.jinf.2008.08. 008.
27. Health council of the Netherlands (Gezondheidsraad). General vaccination against Hepatitis B revisited 2007.
28. Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. Vaccine 2006; 24:2057-64; PMID:16356598; http://dx.doi.org/10.1016/j. vaccine.2005.11.021.
29. McGuirk P, Johnson PA, Ryan EJ, Mills KH. Filamentous hemagglutinin and pertussis toxin from Bordetella pertussis modulate immune responses to unrelated antigens. J Infect Dis 2000; 182:1286-9; PMID:10979938; http://dx.doi.org/10. 1086/315838.
30. van der Avoort H, Berbers G, van Binnendijk R, Boot H, Feltkamp M, Friesema I, et al. The National Immunisation Programme in the Netherlands. In: Kemmeren J, De Melker H, Editors. Bilthoven: RIVM 2010.
31. Meade BD, Deforest A, Edwards KM, Romani TA, Lynn F, O'Brien CH, et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 1995; 96:570-5; PMID:7659478.
32. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 2008; 335:79-89; PMID:18407287; http://dx.doi.org/10. 1016/j.jim.2008.02.018.
33. Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 1990; 135:121-8; PMID:2273252; http://dx.doi.org/10.1016/0022-1759(90)90264-V.
34. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266-72; PMID:11238206.
35. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984; 149:1034-5; PMID:6610714; http://dx.doi.org/10.1093/infdis/149.6.1034.
36. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100; PMID:6602191; http://dx.doi.org/10.1093/infdis/147.6.1100.
37. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16:1901-6; PMID:9796041; http://dx.doi.org/10.1016/S0264-410X(98)00226-6.
38. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-16; PMID:9796042; http://dx.doi.org/10.1016/S0264-410X(98)00227-8.
39. Hewlett EL, Halperin SA. Serological correlates of immunity to Bordetella pertussis. Vaccine 1998; 16:1899-900; PMID:9796040; http://dx.doi.org/10.1016/ S0264-410X(98)00228-X.
40. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA. Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 2009; 67:301-8; PMID:19687529.
41. Clopper C, Pearson S. The use of confidence or fiducial limits illustrated in the case of the Binomial. Biometrika 1934; 26:404-13; http://dx.doi.org/10.1093/biomet/26.4.404.
42. Tukey J. Exploratory Data Analysis: Addison-Wesley 1977.